CNBX Pharmaceuticals Inc. (CNBX)
USD 0.01
(5.93%)
USD 0.01
(5.93%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.34 Million USD | -54.59% |
| 2022 | 2.95 Million USD | 13.61% |
| 2021 | 2.6 Million USD | -14.77% |
| 2020 | 3.05 Million USD | -7.93% |
| 2019 | 3.31 Million USD | -13.22% |
| 2018 | 3.81 Million USD | 105.33% |
| 2017 | 1.85 Million USD | 372.96% |
| 2016 | 393.17 Thousand USD | -26.71% |
| 2015 | 536.5 Thousand USD | 149.35% |
| 2014 | 215.16 Thousand USD | 271.4% |
| 2013 | 57.93 Thousand USD | 184.13% |
| 2012 | 20.38 Thousand USD | -83.77% |
| 2011 | 125.66 Thousand USD | 358.11% |
| 2010 | 27.43 Thousand USD | -76.13% |
| 2009 | 114.92 Thousand USD | 747.31% |
| 2008 | 13.56 Thousand USD | -41.55% |
| 2007 | 23.2 Thousand USD | 215.89% |
| 2006 | -20.02 Thousand USD | -1212.28% |
| 2005 | 1800.00 USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 207.98 Thousand USD | -20.41% |
| 2024 Q1 | 261.33 Thousand USD | -0.06% |
| 2024 Q3 | 152.27 Thousand USD | -26.78% |
| 2023 Q1 | 346.79 Thousand USD | -27.5% |
| 2023 Q4 | 261.49 Thousand USD | -45.89% |
| 2023 FY | 1.34 Million USD | -54.59% |
| 2023 Q2 | 250.01 Thousand USD | -27.91% |
| 2023 Q3 | 483.24 Thousand USD | 93.29% |
| 2022 Q3 | 635 Thousand USD | -13.04% |
| 2022 FY | 2.95 Million USD | 13.61% |
| 2022 Q1 | 1.11 Million USD | 86.2% |
| 2022 Q2 | 730.26 Thousand USD | -34.23% |
| 2022 Q4 | 478.35 Thousand USD | -24.67% |
| 2021 Q4 | 596.32 Thousand USD | -11.82% |
| 2021 FY | 2.6 Million USD | -14.77% |
| 2021 Q1 | 659.73 Thousand USD | -1.96% |
| 2021 Q2 | 667.86 Thousand USD | 1.23% |
| 2021 Q3 | 676.25 Thousand USD | 1.26% |
| 2020 FY | 3.05 Million USD | -7.93% |
| 2020 Q3 | 692.4 Thousand USD | -20.2% |
| 2020 Q2 | 867.67 Thousand USD | 6.12% |
| 2020 Q1 | 817.61 Thousand USD | -16.72% |
| 2020 Q4 | 672.92 Thousand USD | -2.81% |
| 2019 FY | 3.31 Million USD | -13.22% |
| 2019 Q3 | 781.68 Thousand USD | -12.99% |
| 2019 Q1 | 651.59 Thousand USD | -9.69% |
| 2019 Q2 | 898.36 Thousand USD | 37.87% |
| 2019 Q4 | 981.8 Thousand USD | 25.6% |
| 2018 Q1 | 538.7 Thousand USD | -50.51% |
| 2018 Q4 | 721.53 Thousand USD | -15.58% |
| 2018 FY | 3.81 Million USD | 105.33% |
| 2018 Q3 | 854.71 Thousand USD | -49.82% |
| 2018 Q2 | 1.7 Million USD | 216.2% |
| 2017 Q1 | 102.87 Thousand USD | -11.77% |
| 2017 Q4 | 1.08 Million USD | 129.42% |
| 2017 Q3 | 474.44 Thousand USD | 144.83% |
| 2017 FY | 1.85 Million USD | 372.96% |
| 2017 Q2 | 193.78 Thousand USD | 88.37% |
| 2016 FY | 393.17 Thousand USD | -26.71% |
| 2016 Q3 | 63.84 Thousand USD | -56.92% |
| 2016 Q1 | 50.11 Thousand USD | -74.95% |
| 2016 Q2 | 148.2 Thousand USD | 195.76% |
| 2016 Q4 | 116.6 Thousand USD | 82.63% |
| 2015 Q2 | 56.57 Thousand USD | -55.12% |
| 2015 FY | 536.5 Thousand USD | 149.35% |
| 2015 Q4 | 200.03 Thousand USD | 30.02% |
| 2015 Q3 | 153.84 Thousand USD | 171.94% |
| 2015 Q1 | 126.05 Thousand USD | -14.2% |
| 2014 Q4 | 146.9 Thousand USD | 492.42% |
| 2014 Q3 | 24.79 Thousand USD | -15.37% |
| 2014 Q2 | 29.3 Thousand USD | 107.07% |
| 2014 Q1 | 14.15 Thousand USD | -57.8% |
| 2014 FY | 215.16 Thousand USD | 271.4% |
| 2013 Q2 | 4650.00 USD | -69.21% |
| 2013 Q1 | 15.1 Thousand USD | 251.57% |
| 2013 Q3 | 4650.00 USD | 0.0% |
| 2013 FY | 57.93 Thousand USD | 184.13% |
| 2013 Q4 | 33.53 Thousand USD | 621.12% |
| 2012 Q2 | 1849.00 USD | -81.95% |
| 2012 Q1 | 10.24 Thousand USD | -88.6% |
| 2012 Q3 | 4000.00 USD | 116.33% |
| 2012 Q4 | 4295.00 USD | 7.38% |
| 2012 FY | 20.38 Thousand USD | -83.77% |
| 2011 Q1 | 8808.00 USD | 229.64% |
| 2011 FY | 125.66 Thousand USD | 358.11% |
| 2011 Q4 | 89.9 Thousand USD | 151.4% |
| 2011 Q3 | 35.76 Thousand USD | 734.34% |
| 2011 Q2 | 4286.00 USD | -51.34% |
| 2010 Q4 | 2672.00 USD | 23.65% |
| 2010 Q3 | 2161.00 USD | 21.95% |
| 2010 Q2 | 1772.00 USD | -91.51% |
| 2010 Q1 | 20.87 Thousand USD | -80.53% |
| 2010 FY | 27.43 Thousand USD | -76.13% |
| 2009 FY | 114.92 Thousand USD | 747.31% |
| 2009 Q4 | 107.21 Thousand USD | 12195.53% |
| 2009 Q3 | 872.00 USD | -33.99% |
| 2009 Q2 | 1321.00 USD | -76.03% |
| 2009 Q1 | 5510.00 USD | 143.81% |
| 2008 FY | 13.56 Thousand USD | -41.55% |
| 2008 Q2 | 1802.00 USD | -75.17% |
| 2008 Q1 | 7257.00 USD | 98.39% |
| 2008 Q3 | 2245.00 USD | 24.58% |
| 2008 Q4 | 2260.00 USD | 0.67% |
| 2007 Q2 | 9963.00 USD | 35.0% |
| 2007 Q3 | 2129.00 USD | -78.63% |
| 2007 Q4 | 3658.00 USD | 71.82% |
| 2007 FY | 23.2 Thousand USD | 215.89% |
| 2007 Q1 | 7380.00 USD | 121.75% |
| 2006 Q2 | 5514.00 USD | -8.36% |
| 2006 FY | -20.02 Thousand USD | -1212.28% |
| 2006 Q1 | 6017.00 USD | 0.0% |
| 2006 Q3 | 2381.00 USD | -56.82% |
| 2006 Q4 | -33.93 Thousand USD | -1525.16% |
| 2005 FY | 1800.00 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -0.458% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 73.393% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 95.461% |
| Nascent Biotech, Inc. | 2.22 Million USD | 39.838% |
| Rebus Holdings, Inc. | 664 Thousand USD | -102.04% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 96.399% |
| Qrons Inc. | 643.67 Thousand USD | -108.419% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -244.369% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 97.664% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -222.891% |
| Skye Bioscience, Inc. | 13.54 Million USD | 90.098% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 98.454% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 72.721% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -412.576% |
| SQZ Biotechnologies Company | 85.61 Million USD | 98.433% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 53.997% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 10.677% |
| Mesoblast Limited | 5.9 Million USD | 77.27% |
| Marizyme, Inc. | 19.23 Million USD | 93.027% |
| Genus plc | 147.7 Million USD | 99.092% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 84.719% |
| Pharming Group N.V. | 225.49 Million USD | 99.405% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 34.517% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 83.912% |
| ContraFect Corporation | 56.88 Million USD | 97.642% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 69.57% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 9.279% |
| IMV Inc. | 37.7 Million USD | 96.442% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 51.922% |
| MultiCell Technologies, Inc. | 567.42 USD | -236328.924% |
| ONE Bio Corp. | 6.44 Million USD | 79.181% |
| Accustem Sciences Inc. | 3.74 Million USD | 64.191% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 98.439% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -152.188% |
| Q BioMed Inc. | 3.43 Million USD | 60.963% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 94.572% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 48.943% |
| Biomind Labs Inc. | 994.18 Thousand USD | -34.94% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 98.649% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 23.762% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 80.031% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 28.043% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 5466.18% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 91.621% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 26.895% |
| GB Sciences, Inc. | 1.42 Million USD | 5.559% |
| Alpha Cognition Inc. | 9.7 Million USD | 86.178% |
| HST Global, Inc. | 140.9 Thousand USD | -852.078% |
| CSL Limited | 3.44 Billion USD | 99.961% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -19.258% |
| Halberd Corporation | 74.84 Thousand USD | -1692.503% |
| Enzolytics Inc. | 2.17 Million USD | 38.447% |
| Agentix Corp. | 1.37 Million USD | 2.202% |
| Resverlogix Corp. | 12.71 Million USD | 89.447% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 63.252% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.913% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -28.5% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 44.217% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 15.057% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 60.6% |
| AVAX Technologies, Inc. | 7.31 Million USD | 81.648% |
| Zenith Capital Corp. | 8.94 Million USD | 84.999% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.837% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -7600.735% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 45.362% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -682.201% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 30.161% |
| Kadimastem Ltd | 2.41 Million USD | 44.337% |
| Helix BioMedix, Inc. | 1.97 Million USD | 31.972% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 87.655% |
| BioStem Technologies, Inc. | 22.97 Million USD | 94.161% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -639.204% |
| LadRx Corporation | 3.81 Million USD | 64.805% |
| Cell Source, Inc. | 4.32 Million USD | 68.984% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -45.266% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -45.266% |
| NovAccess Global Inc. | 2.46 Million USD | 45.615% |
| Affymax, Inc. | 39.38 Million USD | 96.594% |
| Itoco Inc. | 919.14 Thousand USD | -45.956% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 68.348% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -19.888% |
| Mobile Lads Corp. | 554.54 Thousand USD | -141.918% |
| CytoDyn Inc. | 18.05 Million USD | 92.571% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -5230.148% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -509.577% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 5.511% |
| SYBLEU INC | 160.87 Thousand USD | -733.9% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 26.139% |
| International Stem Cell Corporation | 5.27 Million USD | 74.549% |
| Bioxytran, Inc. | 3.82 Million USD | 64.882% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -2448.431% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -6494.627% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 96.301% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 17.086% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -82.316% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 56.877% |
| Neutra Corp. | 243.82 Thousand USD | -450.217% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 92.315% |
| PureTech Health plc | 144.59 Million USD | 99.072% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 93.453% |
| IXICO plc | 4.7 Million USD | 71.499% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 84.75% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 98.861% |
| CSL Limited | 3.89 Billion USD | 99.966% |
| Cellectis S.A. | 97.32 Million USD | 98.622% |